Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) announced the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection (CDI). The research also presented the substantial mortality and frequent complications associated with CDI.

Read more information regarding Optimer's presentation plus more stock market news at: http://pennyomega.com/?p=14158